Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO...

Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at
BIO International Convention Today

GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai
Corporation (Nasdaq: IOMI) announced that its Chief Scientific Officer,
Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the Chief Scientific
Officer of Intercell AG (VSE: ICLL), will speak today at the Biotechnology
Industry Organization's International Convention at a breakout session titled
"Breakthrough Technologies, Burgeoning Business."
The session will begin at 4 p.m. in room 30A of the San Diego Convention
Center.
As previously announced, Iomai and Intercell AG have entered into an
agreement whereby Iomai has agreed to be acquired by Intercell AG.
About Iomai Cooperation
Iomai Corporation discovers and develops vaccines and immune system
stimulants, delivered via a novel, needle-free technology called
transcutaneous immunization (TCI). TCI, discovered by researchers at the
Walter Reed Army Institute of Research, taps into the unique benefits of a
major group of antigen-presenting cells found in the outer layers of the skin
(Langerhans cells) to generate an enhanced immune response. Iomai is
leveraging TCI to enhance the efficacy of existing vaccines, develop new
vaccines that are viable only through transcutaneous administration and expand
the global vaccine market. Iomai currently has four product candidates in
development: three targeting influenza and pandemic flu and one to prevent
travelers' diarrhea. For more information on Iomai, please visit
http://www.iomai.com.
Iomai announced on May 12 that it has entered into an agreement with
Intercell AG in which Intercell will acquire Iomai for $6.60 a share.
About Intercell AG
Intercell AG is a growing biotechnology company which focuses on the
design and development of novel vaccines for the prevention and treatment of
infectious diseases with substantial unmet medical need. The Company develops
antigens and adjuvants which are derived from its proprietary technology
platforms and has in-house GMP manufacturing capabilities. Based on these
technologies, Intercell has strategic partnerships with a number of global
pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi
Pasteur, Kirin, and the Statens Serum Institut.
The Company's leading product, a prophylactic vaccine against Japanese
Encephalitis, successfully concluded pivotal Phase III clinical trials in
2006. The Market Authorization Application (MAA) in Europe as well as the
Biological License Application (BLA) with the US Food and Drug Administration
(FDA) for the use of the vaccine to prevent Japanese Encephalitis were
submitted in December of 2007. The licensure application to TGA (Therapeutic
Goods Administration) in Australia was submitted in February of 2008.
The Company's broad development pipeline includes a partnered S. aureus
vaccine in Phase II, a therapeutic vaccine against Hepatitis C in Phase II, a
Pseudomonas vaccine in Phase II, a partnered Tuberculosis vaccine (Phase
I/II), and five products focused on infectious diseases in preclinical
development.
Intercell is listed on the Prime Market of the Vienna Stock Exchange under
the symbol "ICLL".
ISIN: AT0000612601
For more information on Intercell, please visit: http://www.intercell.com
SOURCE Iomai Corporation

Russell P. Wilson, SVP, Chief Financial Officer and General Counsel of Iomai
Corporation, +1-301-556-4478, investors@iomai.com; or Brian Reid of WeissComm
Partners, Inc., +1-703-402-3626, breid@wcpglobal.com, for Iomai Corporation;
or Lucia Malfent, Head of Corporate Communications for Intercell AG,
+43-1-20620-303, LMalfent@intercell.com